48 results about "Retinal cell" patented technology

The invention discloses Hangzhou white chrysanthemum-derived exosome-like nano-vesicles, a preparation method thereof and application of the nano-vesicles in treatment of optic nerve retinal degeneration diseases. In-vitro experiments show that the Hangzhou white chrysanthemum-derived exosome-like nano-vesicles provided by the invention can effectively inhibit glutamic acid-induced retinal cell oxidative stress and mitochondrial injury and improve the cell activity. In-vivo experiments show that the survival rate of ganglion cells in the retina of an NMDA injury model mouse can be remarkably improved by injecting the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle into a vitreous cavity, and the visual electrophysiological function of the NMDA injury model mouse can be improved. The invention provides a new thought and method for treatment of optic nerve retinal degeneration diseases, and has a wide application prospect. In addition, the preparation method of the Hangzhou white chrysanthemum-derived exosome-like nano-vesicle provided by the invention is simple, and has the advantages of low cost, wide applicability, good safety, no animal-derived components and the like.

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The invention belongs to the technical field of seaweed functional products, and particularly relates to fucoidin as well as a preparation method and application thereof, in particular to application of the fucoidin in food and preparation of medicines for adjuvant treatment of age-related maculopathy. According to the invention, alginate lyase is adopted to carry out enzymolysis on seaweed, and the fucoidin with the molecular weight of 20-60 kDa is obtained after treatment of multi-stage alcohol precipitation, hydrogen peroxide degradation and membrane interception. Experimental results show that the fucoidin has the effect of repairing retinal cells, can effectively improve maculopathy, can be used for preparing related products for treating age-related macular degeneration, and provides safer natural material support for treatment of age-related macular degeneration.

The present application relates to the technical field of biological medicine, and particularly relates to application of Crybb2 recombinant protein in treatment and / or prevention of diabetic retinopathy. The present application finds that the use of Crybb2 recombinant protein can improve the activity of müller cells, reduce the level of GFAP, restore the level of GS, reduce inflammation, reduce apoptosis of retinal cells and restore the structure and function of the retina. It can be used for treatment and / or prevention of diabetic retinopathy.

The present invention relates to a method for attenuating retinal cell damage and other neuronal cell damage outside the central nervous system associated with reduced supply of neurotrophin, i.e., nerve growth factor (NGF), induced by glaucoma and other forms of neurodegeneration by orally administering a therapeutically effective amount of an aqueous extract of spearmint to a subject.

The invention relates to the technical field of biological medicine, in particular to application of Crybb2 recombinant protein to treatment and / or prevention of diabetic retinopathy. The application finds that by using the Crybb2 recombinant protein, the muler cell activity can be improved, the GFAP level can be reduced, the GS level can be recovered, the inflammation can be alleviated, the apoptosis of retinal cells can be reduced, and the structure and function of the retina can be recovered. The compound can be used for treating and / or preventing diabetic retinopathy.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1A (or a variant thereof) or Formula A, an amino acid sequence set forth in Table 1B (or a variant thereof) or Formula B, or an amino acid sequence set forth in Table 1C (or a variant thereof) or Formula C, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and / or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and / or AAV capsid polypeptides are provided.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

The present disclosure provides an isolated photosensitive opsin protein that rapidly, reversibly and accurately restores the sensitivity of retinal cells to light by activating Gq signaling.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, it provides AAV vectors (e.g., AAV2 vectors) containing AAV capsid polypeptides, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and / or expressing such nucleic acid molecules, and methods and materials for preparing or using such vectors and / or AAV capsid polypeptides comprising the amino acid sequences shown in Table 1A (or variants thereof) or Formula A, Table 1B (or variants thereof) or Formula B, or Table 1C (or variants thereof) or Formula C.

A tapered dynamic out-of-focus lens comprises a first group of lenses and a second group of lenses, the first group of lenses and the second group of lenses comprise left lenses and right lenses, and the left lenses and the right lenses of the first group of lenses and the second group of lenses comprise lens substrates. A circular central optical area at the circle center, an annular defocusing area at the periphery of the central optical area and an annular edge area at the periphery of the defocusing area are arranged on the lens base body. Dynamic defocus intervention is realized by periodically and alternately wearing the first pair of glasses and the second pair of glasses, so that retinal cells periodically and alternately receive defocus stimulation and alternately rest and recover within a set time, and the problem that the myopia prevention and control efficacy is greatly weakened on the premise that human eyes have self-adaptability is effectively solved.

The present disclosure provides a polynucleotide construct comprising an expression cassette comprising a nucleotide sequence encoding a polypeptide comprising an opsin5 (OPN5), operably linked to a promoter. The present disclosure also provides an rAAV for expressing the OPN5 in retinal cells, such as RGCs.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting of retinal cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

Enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of eye or central nervous system (CNS) disorders, wherein the rAAV comprises one or more amino acid substitutions that interact with the heparan sulfate proteoglycan. The invention provides methods for enhancing retinal cell transduction and methods for treating eye diseases with enhanced compositions of rAAV particles. Furthermore, enhanced recombinant adeno-associated viruses (rAAVs) (e.g., rAAV2, rAAVrh8R, etc.) are provided herein for improved gene therapy of CNS disorders. The invention provides methods for delivering the rAAV to the CNS, methods for treating CNS disorders with enhanced compositions of rAAV particles, and kits for delivering the rAAV to the CNS and / or treating a CNS disorder.

An adeno-associated virus (AAV) capsid protein variant with improved infectivity to target cells and transduction efficiency, and its use are disclosed. Specifically, an AAV2 variant capsid protein selected through directed evolution for gene delivery to retinal cells, a recombinant AAV vector containing the same, and its use as a gene delivery vehicle to retinal cells are disclosed.

The present disclosure belongs to the field of viral vectors, and provides AAV capsid protein variants and applications thereof. The capsid protein variants are obtained by inserting a polypeptide into a wild-type AAV viral capsid protein. The capsid protein variants of the present disclosure can effectively improve the retinal cell infectivity of AAV viruses.

This invention relates to the technical field of light-emitting diodes (LEDs), and discloses an epitaxial structure for a multi-band LED and its fabrication method. The epitaxial structure includes a substrate, a buffer layer, an N-type semiconductor layer, a low-temperature stress relief layer, a multi-quantum-well (MBU) light-emitting layer, an electron blocking layer, and a P-type semiconductor layer. The MBU light-emitting layer comprises a first MBU layer, a second MBU layer, a third MBU layer, and a fourth MBU layer stacked sequentially. Each MBU layer includes periodically alternating InGaN quantum well layers and a variable barrier height control layer. The variable barrier height control layer comprises five sub-layers stacked sequentially on the InGaN quantum well layers. The emission wavelength of the first MBU layer is λ1, the second MBU layer is λ2, the third MBU layer is λ3, and the fourth MBU layer is λ4, where λ1 > λ2 > λ3 and λ3 = λ4. Implementing this invention can produce a healthy full-spectrum white LED light source with a high color rendering index, a low proportion of short-wavelength blue light (causing minimal damage to retinal cells), and high luminous efficiency.

A device for the treatment of ocular disorders, in particular disorders of the internal tissues of the eye, includes a mask and a plurality of light-emitting diodes distributed on the internal surface of the mask. The plurality of light-emitting diodes includes at least one matrix of light-emitting diodes arranged in areas of the internal surface of the mask adapted to be facing, in use, the ocular areas of the user and are configured to emit electromagnetic radiations adapted to stimulate the cellular function of the retinal cells.

The application relates to a retinal cell type-based visual function related parameter acquisition system and belongs to the technical field of medical auxiliary systems. The application aims to accurately acquire a retinal cell type-based visual function related parameter acquisition system of L cone, M cone, S cone, ipRGCs and other different retinal cell type function related physiological parameters. The system of the application comprises a stimulation presentation module, a brightness calibration module, a biological signal acquisition module, a multi-dimensional parameter extraction and cell type specific parameter decoupling module, a parameter analysis and standardized output module, a user interaction module and a data storage module. The application can provide a portable, objective, non-invasive and cell type specific retinal function related parameter acquisition technology, provide comprehensive and reliable technical support for visual function evaluation, is suitable for large-scale parameter acquisition and home monitoring, and solves many limitations of the prior art.

Provided are a capsid-modified adeno-associated virus (AAV), preparation therefor and a use thereof. Specifically, provided are an AAV capsid protein variant, a preparation method for recombinant AAV particles comprising a variant capsid protein, and compared with an AAV containing an unmodified parental AAV capsid protein, increased infectivity and gene product expression thereof in target cells such as retinal cells.

The present invention relates to modified recombinant adeno-associated virus (AAV) capsid proteins and AAV particles thereof. In one aspect, the modified recombinant AAV particles provide for increased transduction of retinal cells when compared to the effect of a recombinant AAV particle that does not comprise the modification. The present invention also relates to nucleic acids encoding the modified AAV capsid proteins and AAV particles thereof.

The present disclosure provides nucleic acids comprising one or more miRNA binding sequences to reduce off-target effects and maintain retinal cell-specific expression. Compositions comprising the nucleic acids and use of the compositions for the treatment of ophthalmic diseases are further provided.

The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject. In particular, isolated polynucleotides and recombinant vectors encoding a particular isoform called Crumbs 1-B (CRB1-B) are provided. The CRB1-B encoding polynucleotides may be operably linked to a heterologous promoter capable of expressing the isoform in a retinal cell. Kits employing such compositions are also provided.

The application provides application of human umbilical cord mesenchymal stem cell-derived Supermeres in preparation of a medicine for treating diabetic retinal fibrosis, and belongs to the technical field of biological medicine; the application research finds that the human umbilical cord mesenchymal stem cell-derived Supermeres can significantly inhibit retinal cell fibrosis, reduce the expression of fibrosis marker proteins alpha-SMA, col-1a1 and Fibronectin, compared with human umbilical cord mesenchymal stem cell-derived EVs, can not only better inhibit the occurrence of fibrosis, but also more significantly inhibit cell apoptosis and promote cell proliferation, so that the technical effect of treating retinal fibrosis is achieved; the human umbilical cord mesenchymal stem cell-derived Supermeres have good application in preparation of the medicine for treating diabetic retinal fibrosis.

This document relates to AAV vectors (e.g., AAV2 vectors). For example, AAV vectors (e.g., AAV2 vectors) containing an AAV capsid polypeptide that includes an amino acid sequence set forth in Table 1 (or a variant thereof) or Formula A, such AAV capsid polypeptides, nucleic acid molecules encoding such vectors, nucleic acid molecules encoding such AAV capsid polypeptides, host cells containing and / or expressing such nucleic acid molecules, and methods and materials for making or using such vectors and / or AAV capsid polypeptides are provided.

Novel anti-C3 antibodies and anti-C5 antibodies are provided that are capable of modulating complement activity by specifically binding to the human complement factors C3, C3a, C3b and / or C5. Also described herein are recombinant adeno-associated virus (AAV) (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding an anti-C3 antibody and / or an anti-C5 antibody. Also provided are methods of delivering a transgene to the retina, as well as methods of treating dry age-related macular degeneration and map-like atrophy secondary to an age-related macular degeneration disorder by contacting retinal cells with rAAV.

The invention relates to the technical field of biological medicines, in particular to an AAV virus vector carrying a VEGFB (vascular endothelial growth factor B) gene and application of the AAV virus vector in preparation of a medicine for treating retinitis pigmentosa. The invention provides an AAV virus vector carrying a VEGFB gene and application of the vector in preparation of a medicine for treating retinitis pigmentosa. A VEGFB gene is combined with an AAV virus vector to construct a recombinant virus vector capable of effectively transfecting retinal cells and expressing VEGFB protein, and effective treatment on retinitis pigmentosa is realized by utilizing biological functions of oxidation resistance, apoptosis resistance, angiogenesis inhibition and the like of the VEGFB protein.

A surgical clamp for aligning the margins of incised or wounded tissue has jaws with parallel clamping faces, and a handle for manipulating the clamp to align the margins of the tissue. The jaws are in a normally closed position, however they can be opened by compressing the handle to open the jaws. Prongs project from the inferior surface of the jaws. The clamp is positioned in a desired position over the margins of a wound to be closed, the prongs engage the margins of the wound to be aligned, and the jaws are closed by releasing compressive force on the handle. As the jaws close the prongs help move the tissue into alignment. Suture guide slots through the jaws assist in the placement of precisely placed sutures across the incision. The disclosed surgical clamp is particularly suited for selectively closing and reopening surgical incisions, such as a sclerotomy incision in the eye. Methods are disclosed for using the clamp during intraocular and other surgical or minimally invasive procedures. In one example the clamp is used during implantation into the retina of a scaffold on which choroid and retinal pigment epithelium cells and retina grow in a three-dimensional matrix that mimics the native structure of the retina.

Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are a method for delivering the transgene to the retina, and a method for treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration by contacting retinal cells with rAAV. The variant AAV capsid protein may contain a peptide insertion ("heterogeneous peptide" or "peptide insertion") of about 7 to 20 amino acids within the GH loop of the capsid protein, preferably within the surface-exposed region of the GH loop, compared to the corresponding parental AAV capsid protein.